STOCK TITAN

ANNABIDIOL (ACBD) Stock News

ACBD OTC
Rhea-AI Summary

AnnaBidiol has entered into a merger agreement with Targatek, an AI corporate leadership SaaS company. The agreement includes a reverse merger, resulting in Targatek shareholders receiving 85% of AnnaBidiol's common stock after 35,000,000 shares of common stock and 500,000 Series A Preferred shares are canceled. The merger is set to close by September 15, 2024. AnnaBidiol plans to raise $750,000 in a private placement to fund operations and stock redemption. Post-merger, the company expects to reduce its outstanding common shares from 39,990,306 to 30,260,000, with zero preferred shares, warrants, or options remaining. William J. Adams Jr., Targatek's CEO, highlighted the synergy and growth potential of the merger.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.95%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.6%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
68%
Tags

FAQ

What is the current stock price of ANNABIDIOL (ACBD)?

ANNABIDIOL (ACBD) last closed at $0.84.

What is the market cap of ANNABIDIOL (ACBD)?

The market cap of ANNABIDIOL (ACBD) is approximately $4.0M.